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A Multicenter Pilot Study to Evaluate
the Effect of EVOO on Lipid Parameters
Katherine Brady, Caroline Knight, Stacia Kozidis, Ralph Hamill, MD, FACC

BACKGROUND

METHODS

Treatment options for low high-density lipoprotein (HDL)
remain limited, though evidence suggests benefits of high
HDL levels on lifespan at a rate of 14% increase in survival
to the age of eighty five1.
Olive oil consumption is associated with reduced
cardiovascular disease events and mortality, thought to be
due to the increased function and concentration of HDL1, 3.
Extra virgin olive oil (EVOO) has been shown to increase
HDL by 8-12%2; moreover, a relationship between
increased EVOO consumption is associated with reduced
CVD risk3. Most olive oil studies1, 7 have been based on a
longitudinal observational study design.
Polyphenols in olive oil are thought to contribute to its
antioxidant and anti-inflammatory properties6. These are
large, naturally occurring molecules found in varying
concentrations in fruits, vegetables, cereals, tea, and coffee.
Among EVOOs, the concentration of polyphenols is
dependent on variables such as climate, harvest,
processing, and storage factors. Less than 10% of retail
olive oil has the recommended polyphenol concentration
above 250 ppm, the minimum intake required to have an
antioxidant effect in a balanced diet4, 5, 6. Most studies
relating olive oil exposure and cardiovascular disease do
not distinguish between olive oil types or polyphenol
concentration.

PURPOSE
The purpose of this multi-center, double-blinded pilot study
was to determine if EVOO has a positive effect on HDL
cholesterol levels and anti-inflammatory markers for
subjects diagnosed with CVD and to determine if the
polyphenol concentration is proportional to those effects.
Subjects completed consecutive 28-day periods (with a 14day washout between) in which they will either consume
the low polyphenol EVOO daily or the high polyphenol
EVOO. In a double-blinded manner, each subject was his
or her own control with a 14-day washout between study
periods. HDL levels and other parameters were be
measured after each period of the protocol. We anticipated
HDL levels will improve with both olive oils. We expect
the high polyphenol concentration EVOO would show a
greater effect than the EVOO with a low polyphenol
concentration.
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Oils
A generic brand EVOO was obtained from the local chain grocery store. EVOO with a reported high polyphenol concentration
was obtained from a local olive oil specialty store. Both oils were sent to Eurofins Microbiology Laboratories, Inc. for testing
of polyphenol concentration.
Generic – 286 mg/kg polyphenols
Specialty – 364 mg/kg polyphenols

Inclusion Criteria
Males and females 18 years of age or older
Known cardiovascular disease
HDL < 40 at screening

Exclusion Criteria
Currently using EVOO on a daily basis
Change in use of lipid lowering medications or supplements in the past 90 days
Significant change in diet or exercise in the past 30 days

Assessments
Standard Lipid panels are obtained 5 times during the subject’s participation
• Baseline
• After first 28 days of EVOO
• After 2 week washout
• After second 28 days of EVOO
• After 2 week washout
Serum total lipid profiles before and after each study phase will be analyzed in the mass spectrometry core at the Maine
Medical Center Research Institute (MMCRI) once the study is complete. Inflammatory markers, including CRP, IL-6 and
TNF-alpha, will be determined by enzyme-linked immunosorbent assay (ELISA). Lipidomic profiles of white blood cells and
careolin-1 protein levels will also be analyzed.
Subjects maintain a study diary documenting each dose of EVOO. Compliance with EVOO consumption is calculated from
the diary (%). Study compliance is also measured by ounces of product returned (%).

0
% male

Avg age

Pen Bay Med Ctr

MidCoast Hospital

Avg baseline HDL

Scarborough

To date, seventeen subjects with known cardiovascular
disease and HDL <40 have been recruited from three study
sites, Pen Bay Medical Center, Mic Coast Hospital and
Maine Medical Partners Cardiology in Scarborough.
Fourteen subjects completed the study. The results of this
ongoing study remain blinded.

CHALLENGES
The small pool of potential subjects has made recruitment
difficult. The COVID-19 pandemic has also presented
challenges with enrollment stopping during the major
surges. Subjects are again enrolled, and recruitment is
active at this time.
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